COVID-19 information for patients and consumers

As the coronavirus (COVID-19) continues to affect communities around the world, our thoughts are with those of you who are impacted.

We are operating with a high degree of care as we protect our patients, customers and employees during this unprecedented and difficult time. 

We believe it is our responsibility to prioritise two things:

  • Our commitment to supporting the health and safety of our patients, customers and employees
  • Protecting our ability to manufacture and supply medicines, vaccines and consumer products for patients

Consistent with our values and role as a science-led global healthcare company, we will continue to make decisions informed by the latest science and in consultation with leading health authorities. We are implementing a variety of measures to ensure the health and well-being of our patients, our customers, our employees and our communities.

Our COVID-19 solutions

How we're using our science, technology, portfolio and resources to support development of products for prevention and treatment of COVID-19 and the overall global response.

Ensuring medicine supply and access

We are closely monitoring all parts of our supply chains, proactively developing contingency plans to help us respond to the situation. We have taken a number of measures to support supply of our products, including: prioritising medically critical products; building capacity to respond faster to unpredictable demand in some of our key consumer healthcare products; and working with logistics service providers to find alternative distribution routes. We are experiencing some delays with distribution and delivery of our products to customers as countries around the world introduce different virus containment measures, such as border closures and flight suspensions. Our focus is to avoid or minimise any potential delivery delays or disruptions, closely monitor what is happening and keep our customers informed.

What is the impact of COVID-19 on GSK’s supply chain? What measures have you taken to protect and ensure supply?

We are closely monitoring all parts of our supply chains, proactively developing contingency plans to help us respond to the situation.

We have taken a number of measures to support supply of our products, including: prioritising medically critical products; building capacity to respond faster to unpredictable demand in some of our key consumer healthcare products; and working with logistics service providers to find alternative distribution routes.

We are experiencing some delays with distribution and delivery of our products to customers as countries around the world introduce different virus containment measures, such as border closures and flight suspensions.

Our focus is to avoid or minimise any potential delivery delays or disruptions, closely monitor what is happening and keep our customers informed.

Back to top

Can I receive my GSK prescribed medication without visiting a pharmacy/hospital?

As the situation varies in each country, please contact your local community or hospital pharmacy to see what options they are able to provide.

Back to top

Can I take my intravenous medication at-home?

This may be an option for certain medicines. Please contact your treating doctor regarding this possibility.

Back to top

Where can I find information about a GSK medicine I am taking?

For questions or concerns about our products, vaccines, and/or product availability, please contact us.

Back to top

Conducting clinical trials

Our priority is the safety and well-being of those who support and participate in our clinical trials and our employees. We have issued guidance to clinical trial investigators and we are implementing proactive measures to protect the safety of study participants, staff at our clinical trial sites and our employees while ensuring regulatory compliance and the scientific integrity of our clinical trials. 

Has COVID-19 impacted GSK’s clinical trials?

Our priority is the safety and well-being of those who support and participate in our trials and our employees. As such, we are implementing proactive measures to protect the safety of study participants, staff at our clinical trial sites and our employees while ensuring regulatory compliance and the scientific integrity of our clinical trials. 

At this time, GSK remains supportive of enrolling new patients into ongoing clinical studies, provided that investigators are confident they will be able to conduct the protocol specified safety and efficacy monitoring required for each study.

There may be exceptional cases that require GSK to pause individual trial enrollment. Such decisions will be taken on a case by case basis considering the therapeutic area and the patient population involved in the clinical study.

For new clinical trials, and as appropriate, GSK will delay study initiation and re-evaluate as the situation evolves.

For clinical trials for vaccines, given the specific benefit / risk considerations pertinent to clinical trials with prophylactic vaccines, GSK has decided to pause recruitment of additional trial participants on a country by country basis until further notice as we continuously assess the evolving COVID-19 situation.

Back to top

I am currently in a GSK clinical trial. Who can I contact regarding my participation?

Please contact your study doctor who will be able to provide guidance on your participation in the study.

Back to top

Can I participate in a GSK clinical study for COVID-19?

All GSK sponsored COVID-19 clinical studies can be found on ClinicalTrials.gov.

Back to top

Caring for our people and communities

We are taking several measures to protect the well-being of our employees and the communities in which we operate. We are moving to virtual interaction approaches to ensure we can continue to support the patient community with resources and planned educational programs as appropriate.

Supporting STEM education at home

We are supporting teachers and parents to help bring STEM (science, technology, engineering, and mathematics) to life for students away from the classroom. We have made available free UK curriculum-linked resources that are perfect for young people aged 11-14, to do at home. There are a range of topics to discover, such as understanding how we breathe, how an arm works and exploring data science. Resources include independent student sheets and engaging hands-on activities that require little equipment.

As part of our “STEM at home” series, we’ve also added fun, practical experiments for families to do together, encouraging students to become lab scientists for the day. Check out our at home filter to start exploring our resources.

Contributing to the fight against COVID-19

Since the outbreak, we have been actively exploring ways to help, with our science and expertise, alongside protecting the health and wellbeing of our people and managing our global supply chains to support patients and consumers who depend on our products.

We are collaborating with companies and research groups across the world working on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. In addition to vaccines, we are also supporting screening and research into potential medicines for COVID-19.

Find out more about how we're supporting global efforts to tackle the virus below.
   

What is an adjuvant?

An adjuvant is added to some vaccines to enhance the immune response, thereby creating a stronger and longer lasting immunity against infections than the vaccine alone. 

What is an adjuvanted vaccine?

An adjuvanted vaccine combines both an antigen and an adjuvant. The use of an adjuvant is of particular importance in a pandemic situation since it can reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and made available to more people. 

What is antibody therapy?

Our immune system fights infections by recognising antigens on the surface of invading viruses and bacteria. It makes antibodies to destroy antigens. Antibody therapy uses monoclonal antibodies which are produced, or cloned, from immune cells in a lab. By targeting specific antigens, they could help our immune system fight diseases such as COVID-19.